Led · Series D · Mar 2022

Smartee focuses on R&D of original digital invisible orthodontics technology and provides medical design, manufacturing, sales and services for customized clear aligners. Founded in 2004 by Yao Junfeng, the company operates medical design centers with a team of hundreds and has self-developed automated manufacturing bases in Jiaxing, Zhejiang Province and Ziyang, Sichuan Province. It has designed more than 500,000 cases and produces over 10 million invisible aligners annually. Smartee serves doctors and consumers across markets including the USA, Canada, Colombia, Mexico, the UK, Spain, Portugal, Saudi Arabia, Egypt, Australia, Singapore, the Philippines and Thailand. The company intends to use recent funding to accelerate industrial layout in invisible orthodontics, promote continuous R&D and innovation, strengthen brand building and team development, and expand market share domestically and overseas. In March 2022 Smartee completed a Series D financing round to support these initiatives. Smartee is a Shanghai-based developer of invisible orthodontics and digital orthodontic products, positioning itself as a domestic leader in China's invisible orthodontics market. In March 2019 the company completed a Series C financing described as "hundreds of millions of yuan." Smartee says the funds will be used mainly to expand its automated production line and to upgrade the "Smartee" brand logo. The company emphasizes talent recruitment and technological innovation as cornerstones for future growth and aims to lead the era of digital orthodontics in China. Smartee previously closed a Series B in 2017 (led by bioVENTURE), and continued institutional investor support is highlighted in the Series C announcement.

Led · Series C · Jun 2021

Oriental Qiyin provides clinical speech development screening, early intervention, clinical training, and autism intervention services for children. Founded in 2007, the company has grown into the country's largest specialist chain in its sector, operating 45 direct-run centers across more than 19 cities including Beijing, Shanghai, Shenzhen and Guangzhou. It employs over 1,200 professional rehabilitation therapists and has served more than 200,000 children to date. The company emphasizes clinical practice, curriculum R&D and professional talent training, including partnerships with the University of Newcastle (Australia) and Beijing Language and Culture University to build therapist training systems. Oriental Qiyin plans to continue expanding its nationwide direct-center network, extend its course offerings across different needs, and integrate big data and AI with clinical practice to create an online-plus-offline rehabilitation service ecosystem. The firm positions itself to localize international standards for speech and autism intervention while addressing a large national talent gap through systematic training and academic cooperation. 东方启音 offers professional speech-therapy services and training programs, delivering both online and offline courses that address oral muscle and cognitive development. Its therapies are applied to children with cerebral palsy, Down syndrome, hearing impairment, ADHD, developmental delay, and autism, and the company also provides language-improvement courses for typically developing children and rehabilitation programs for adults (stuttering, post-stroke aphasia, post-surgery). The company has imported and promoted international speech-therapy techniques and works with multiple international partners to professionalize training, devices, teaching materials and software. Strategic partnerships include STAR Autism Support (collaboration on Mandarin autism training courses since 2016) and the University of Newcastle to standardize local course standards and build data-driven training plans. 东方启音 runs multiple OST-STAR centers using standardized curricula and has participated in public welfare screening and early-intervention campaigns alongside charities. Financially, the company completed a $25.0M Series B financing, which management says will support continued growth and talent development.

Led · Equity · Dec 2020

MicroTech Medical Co., Ltd. announced it raised CNY 575 million in a funding round on December 8, 2020. The capital was provided by a group of new and returning investors. The round was co-led by Tencent Holdings Ltd., IDG Capital Partners Co., Ltd., and Taikang Qianzhen Fund. Other participants included CICC Jia Cheng Investment Management, Sanzheng Health, China Everbright Limited (SEHK:165), Zhongjin Pucheng Investment, and 3H Health Investment Management. Returning investors included Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Lilly Asia Ventures, CD Capital, Shanghai Guofang FOF Equity Investment Management Co., Ltd., and Zhejiang Juren Capital Management Co., Ltd. The articles do not disclose use of proceeds, valuation, or operating metrics.

Led · Series B · Nov 2017

EOC Pharma focuses on developing in-licensed oncology drugs for the China market. The company acquires or in-licenses cancer therapies and advances them through development in China. Its near-term plan, as reported, is to progress those in-licensed oncology candidates within China. The article reports a $71 million Series C financing to support that China-focused development. No operating metrics, revenue figures, pipeline details, or partnership names were disclosed in the article. EOC Pharma is a fast-growing, Shanghai-based biopharmaceutical company that in-licenses innovative global oncology products and develops, manufactures and commercializes them for China. The company has a pipeline of six novel products from global biopharmaceutical partners, including two innovative small molecules expected to enter Phase 3 registration studies in China in 2018 for breast cancer and gastric cancer. Its pipeline also includes innovative biologics being developed for indications in immuno-oncology and tumor metastasis. EOC is building a fully integrated manufacturing, development and commercialization platform and is a spin-off of the oncology division of Eddingpharm. The company plans to use new funding to advance its mid- and late-stage clinical pipeline and to in-license additional late-stage oncology assets. Management highlights a track record in strategic partnering and commercialization in China and intends to leverage an improved clinical and regulatory environment and a rapidly growing healthcare market.